Indication
Epstein-Barr Virus Associated Lymphoproliferative Disorder
1 clinical trial
1 product
Clinical trial
An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory LymphomasStatus: Recruiting, Estimated PCD: 2025-07-01